← Back to Search

Antioxidant

MitoQ for Peripheral Arterial Disease

N/A
Recruiting
Led By Iraklis Pipinos, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
Positive history of chronic claudication
Must not have
Rest pain or tissue loss due to PAD (Fontaine stage III and IV)
Acute lower extremity ischemic event
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before and after 6 months of treatment with mitoq or placebo
Awards & highlights

Summary

This trial aims to investigate if taking MitoQ for six months can help improve the symptoms and function of people with peripheral artery disease, specifically those experiencing leg pain while walking. We will be looking at

Who is the study for?
This trial is for individuals with peripheral artery disease (PAD) or peripheral vascular disease (PVD), who experience leg pain while walking. Participants should be willing to undergo various assessments, including muscle oxygen tests, walking evaluations, quality of life surveys, ankle pressure measurements, and a needle biopsy.
What is being tested?
The study investigates whether MitoQ supplementation over six months can improve walking ability and daily activity levels in PAD patients with intermittent claudication. It also examines the impact on muscle health and overall quality of life.
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort from the needle biopsy procedure and any reactions related to MitoQ supplementation which could vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with blocked arteries in my legs.
Select...
I have a history of leg pain when walking.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe leg pain or tissue loss because of poor blood flow.
Select...
I recently had a blockage in the blood flow to my legs.
Select...
My ability to walk is mainly limited by non-claudication issues like joint, nerve, or systemic diseases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after 6 months of treatment with mitoq or placebo
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after 6 months of treatment with mitoq or placebo for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Walking Impairment: maximum treadmill distance
Secondary outcome measures
Calf muscle blood vessel health
Calf muscle cell damage
Calf muscle fibrosis
+10 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: MitoQActive Control6 Interventions
Participants will be placed on a 24-week regimen of oral dosing with MitoQ. The patients will take two 20 mg caps of MitoQ on empty stomach, each morning
Group II: PlaceboPlacebo Group6 Interventions
The patients will take two identical caps of matched placebo on empty stomach, each morning

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
554 Previous Clinical Trials
1,145,376 Total Patients Enrolled
14 Trials studying Peripheral Arterial Disease
543 Patients Enrolled for Peripheral Arterial Disease
Iraklis Pipinos, MDPrincipal InvestigatorUniversity of Nebraska
~36 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top